A detailed history of Peloton Wealth Strategists transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Peloton Wealth Strategists holds 13,810 shares of NBIX stock, worth $2 Million. This represents 0.79% of its overall portfolio holdings.

Number of Shares
13,810
Previous 14,910 7.38%
Holding current value
$2 Million
Previous $1.87 Million 3.42%
% of portfolio
0.79%
Previous 0.77%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 17, 2025

SELL
$123.98 - $146.67 $136,378 - $161,337
-1,100 Reduced 7.38%
13,810 $1.94 Million
Q2 2025

Aug 13, 2025

SELL
$87.54 - $128.18 $7,003 - $10,254
-80 Reduced 0.53%
14,910 $1.87 Million
Q1 2025

May 16, 2025

BUY
$107.22 - $153.29 $93,817 - $134,128
875 Added 6.2%
14,990 $1.66 Million
Q4 2024

Feb 05, 2025

BUY
$111.62 - $139.44 $1.18 Million - $1.48 Million
10,600 Added 301.56%
14,115 $1.93 Million
Q3 2024

Nov 15, 2024

BUY
$114.58 - $153.15 $402,748 - $538,322
3,515 New
3,515 $404,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13.9B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Peloton Wealth Strategists Portfolio

Follow Peloton Wealth Strategists and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Peloton Wealth Strategists, based on Form 13F filings with the SEC.

News

Stay updated on Peloton Wealth Strategists with notifications on news.